References
- van Hees P AM, Bakker J H, van Tongeren J HM. Effect of sulphapyridine, 5-aminosalicylic acid and placebo in patients with idiopathic proctitis. A study to determine the active therapeutic moiety of sulphalazine. Gut 1980; 21: 632–5
- Campieri M, Lanfranchi G A, Bazzocchi G, et al. Treatment of ulcerative colitis with high dose 5-aminosalicylic acid enemas. Lancet 1981; 2: 270–1
- Rasmussen S N, Lauritsen K, Tage-Jensen U, et al. 5-Amino-salicylic acid in the treatment of Crohn's disease. Scand J Gastroenterol 1987; 22: 877–83
- Saverymuttu S H, Gupta S, Keshavarzian A, Donovan B, Hodgson H JF. Effect of a slow release 5-aminosalicylic acid preparation on disease activity in Crohn's disease. Digestion 1986; 33: 89–91
- Wellmann W, Schroeder U. New oral preparations for maintenance therapy of Crohn's disease. Can J Gastroenterol 1988; 2(Suppl A)71A–2A
- Brignola C, Iannone P, Pasquali S, et al. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Dig Dis Sci 1992; 37: 29–32
- Healey J NC. Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease. Scand J Gastroenterol 1990; 25(Suppl 172)47–51